MaxCyte, Inc. Depreciation
MaxCyte, Inc. (MXCT) reported Depreciation of $961.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-13
- MaxCyte, Inc. depreciation for the quarter ending 2026-06-30 was $961.00K, a 11.75% decline year-over-year.
- MaxCyte, Inc. depreciation for the quarter ending 2026-03-31 was $1.03M, a 5.16% decline year-over-year.
- MaxCyte, Inc. depreciation for the quarter ending 2025-12-31 was $1.05M, a 0.19% decline year-over-year.
- MaxCyte, Inc. depreciation for the quarter ending 2025-09-30 was $1.06M, a 0.84% decline year-over-year.
- MaxCyte, Inc. depreciation for fiscal 2025 was $4.29M, a 0.65% decline from fiscal 2024.
- MaxCyte, Inc. depreciation for fiscal 2024 was $4.32M.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $961.00K 10-Q · filed 2026-08-13 | $1.99M 10-Q · filed 2026-08-13 | $3.05M derived: sum of 3 quarters · filed 2026-08-13 | $4.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.03M 10-Q · filed 2026-05-13 | $2.08M derived: sum of 2 quarters · filed 2026-05-13 | $3.14M derived: sum of 3 quarters · filed 2026-05-13 | $4.23M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $2.11M derived: sum of 2 quarters · filed 2026-03-25 | $3.20M derived: sum of 3 quarters · filed 2026-08-13 | $4.29M 10-K · filed 2026-03-25 |
| 2025-09-30 | $1.06M 10-Q · filed 2025-11-13 | $2.15M derived: sum of 2 quarters · filed 2026-08-13 | $3.23M 10-Q · filed 2025-11-13 | $4.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.09M 10-Q · filed 2026-08-13 | $2.17M 10-Q · filed 2026-08-13 | $3.23M derived: sum of 3 quarters · filed 2026-08-13 | $4.30M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.09M 10-Q · filed 2026-05-13 | $2.14M derived: sum of 2 quarters · filed 2026-05-13 | $3.21M derived: sum of 3 quarters · filed 2026-05-13 | $4.29M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $2.12M derived: sum of 2 quarters · filed 2026-03-25 | $3.20M derived: sum of 3 quarters · filed 2026-03-25 | $4.32M 10-K · filed 2026-03-25 |
| 2024-09-30 | $1.07M 10-Q · filed 2025-11-13 | $2.15M derived: sum of 2 quarters · filed 2025-11-13 | $3.26M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $1.08M 10-Q · filed 2025-08-06 | $2.19M 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |